Psychiatric and Cognitive Manifestations of Parkinson's Disease
| Status: | Enrolling by invitation |
|---|---|
| Conditions: | Parkinsons Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 21 - Any |
| Updated: | 4/22/2018 |
| Start Date: | June 2006 |
| End Date: | December 2020 |
Psychiatric and Cognitive Manifestations of Parkinson's Disease: A Prospective Cohort Study
Parkinson's Disease (PD) is often thought of as affecting movement only. In fact, most
patients also experience psychiatric and cognitive symptoms, sometimes from the disease
itself, and sometimes as a side-effect of PD medications. The goals of this study are to
evaluate the causes, effects, and clinical correlates of psychiatric and cognitive symptoms
in PD.
patients also experience psychiatric and cognitive symptoms, sometimes from the disease
itself, and sometimes as a side-effect of PD medications. The goals of this study are to
evaluate the causes, effects, and clinical correlates of psychiatric and cognitive symptoms
in PD.
Parkinson's Disease (PD) is defined by the presence of motor symptoms, but in recent years
there has been increasing recognition of non-motor manifestations, including anxiety,
depression, and cognitive symptoms. In addition, PD medications have been shown to cause
impulse control disorders, cognitive changes, and non-motor withdrawal symptoms (dopamine
agonist withdrawal syndrome) when they are discontinued. The goals of this study are to test
the hypothesis that the presence of psychiatric and cognitive symptoms are associated with
greater self-perceived disability (out of proportion to objective deficits), increased
utilization of healthcare resources, and decreased quality of life. In addition, we will
examine the clinical correlates of these psychiatric symptoms. To test these hypotheses, we
will screen PD patients for anxiety, depression, impulse control disorders, and dopamine
agonist withdrawal syndrome, and compare cases and controls with regard to demographic
characteristics, motor features of PD, disability, healthcare utilization, and quality of
life.
there has been increasing recognition of non-motor manifestations, including anxiety,
depression, and cognitive symptoms. In addition, PD medications have been shown to cause
impulse control disorders, cognitive changes, and non-motor withdrawal symptoms (dopamine
agonist withdrawal syndrome) when they are discontinued. The goals of this study are to test
the hypothesis that the presence of psychiatric and cognitive symptoms are associated with
greater self-perceived disability (out of proportion to objective deficits), increased
utilization of healthcare resources, and decreased quality of life. In addition, we will
examine the clinical correlates of these psychiatric symptoms. To test these hypotheses, we
will screen PD patients for anxiety, depression, impulse control disorders, and dopamine
agonist withdrawal syndrome, and compare cases and controls with regard to demographic
characteristics, motor features of PD, disability, healthcare utilization, and quality of
life.
Inclusion Criteria:
- Diagnosis of idiopathic Parkinson's Disease (or healthy control subject)
- Age >=21 and <=99
- Capacity to provide informed consent
- Ability to complete the questionnaires
Exclusion Criteria:
- Clinical diagnosis of dementia
- Terminal illness (life expectancy < 12 months)
- Presence of a neurodegenerative disorder other than Parkinson's Disease
We found this trial at
1
site
New York, New York 10016
Principal Investigator: Melissa J Nirenberg, MD, PhD
Phone: 212-263-7042
Click here to add this to my saved trials
